about
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Blood graft composition after plerixafor injection in patients with NHL.Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and grCD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.Pre-emptive plerixafor injection in lymphoma patients mobilized with chemotherapy plus pegfilgrastim followed by apheresis on the same day.Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.Reproducibility of infrared thermography measurements in healthy individualsBlood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factorBlood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter studyA prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patientsImportance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patientsComparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients
P50
Q38199707-9D85BFF7-06E5-4BDD-8F8C-C9FD82323EBFQ38691698-5703E19A-CC67-48DC-9563-5A5FEA7422C1Q38880504-366FBCD7-85B9-450C-93DD-0498F803F99DQ40896003-4B6AFAB1-2FE6-4A9A-8E29-903C74C86F54Q43524297-3A59E2CA-5CB5-4563-90D5-FBF130BD4E08Q44353274-33824320-09E1-4180-B74A-186F5CD2E4CEQ45940783-B3021CE8-4F96-491B-8BCE-1431191CE930Q47256928-C706CC1D-9C15-4F1A-8A13-8B4207091D92Q47696715-3DF85071-2FB1-424F-B91C-CB505E68AC37Q48130246-113E2171-00FC-4A3D-BC18-A5CB8CDFE2A7Q48266051-9CC89585-1F8E-43E4-8AFE-C2BD66CA0512Q51431592-3A22F198-8868-4843-A9C1-16B39E155F95Q53130499-7C6EA5E5-2CD7-4E82-8352-284A5A846F93Q81051966-9468BA30-B67E-4BDE-B0ED-ED85880B69F8Q83391230-2313F1FE-BEE5-4285-BE54-57BDCD5D9851Q91220568-6FB60C83-0784-40B2-BDB3-03E49B3DBB8EQ92084196-E7058E59-6058-455F-A0CB-F500AFBC11D1Q92187392-E544A01A-8733-43E9-966E-1407A2D5E883Q93204197-2C54DD95-7807-414B-9BA3-2C6545F418B3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ville Varmavuo
@ast
Ville Varmavuo
@en
Ville Varmavuo
@es
Ville Varmavuo
@nl
Ville Varmavuo
@sl
type
label
Ville Varmavuo
@ast
Ville Varmavuo
@en
Ville Varmavuo
@es
Ville Varmavuo
@nl
Ville Varmavuo
@sl
prefLabel
Ville Varmavuo
@ast
Ville Varmavuo
@en
Ville Varmavuo
@es
Ville Varmavuo
@nl
Ville Varmavuo
@sl
P106
P21
P31
P496
0000-0001-5070-6018